Revolution Medicines (RVMD) Q4 2025 earnings review
Accelerating Clinical Progress Met With Ballooning Cash Burn
Revolution Medicines is fully transitioning into a late-stage execution story, and the financial toll is massive. As a pre-revenue clinical biotech, the story revolves entirely around cash burn and clinical milestones. Operating expenses are accelerating aggressively, jumping 67% YoY in Q4 to $361.6M, driven by the simultaneous advancement of multiple Phase 3 trials for daraxonrasib and zoldonrasib. The company enters 2026 with a formidable $2.0B war chest (plus $1.75B in committed capital) but guided for a staggering $1.6B-$1.7B in 2026 operating expenses. The bet is clear: spend whatever it takes to dominate the RAS-mutant oncology market, starting with a pivotal readout for pancreatic cancer in 1H 2026.
🐂 Bull Case
The company has multiple assets in registrational trials. Daraxonrasib is blanketing pancreatic cancer (1L, 2L, adjuvant), and zoldonrasib (G12D) just showed a 63% ORR and 95% disease control rate in combination with FOLFIRINOX for 1L PDAC.
With $2.0B in cash and equivalents, plus another $1.75B available from the Royalty Pharma arrangement, Revolution is fully funded to execute its massive, expensive Phase 3 agenda independently without dilutive equity raises.
🐻 Bear Case
The operational cost of running concurrent global Phase 3 trials is enormous. Q4 R&D expenses jumped 57% YoY, and 2026 total OpEx guidance of $1.65B (midpoint) implies a continued, aggressive acceleration in burn rate.
Initiating and managing 5+ global registrational trials simultaneously across daraxonrasib and zoldonrasib is an operational tightrope. Any delays or safety signals in chemo-combination arms could severely disrupt timelines.
⚖️ Verdict: ⚪
Neutral. The science is progressing rapidly with highly encouraging early combo data, but the financial realities of scaling a global Phase 3 pipeline are setting in. The projected $1.6B+ 2026 spend prices in near-perfect trial execution.
Key Themes
Zoldonrasib Shows Powerful Combination Potential in 1L PDAC
Data released in January showed zoldonrasib + FOLFIRINOX in 1L metastatic pancreatic cancer achieved a 63% partial response rate and 95% disease control rate with a median follow-up of 3.9 months. Crucially, the safety profile was consistent with FOLFIRINOX alone, allowing high dose intensity for zoldonrasib. This validates the combination strategy and derisks the upcoming RASolute 305 and 309 Phase 3 trials.
Imminent Pivotal Readout: RASolute 302
The clock is ticking toward the 1H 2026 data readout for RASolute 302 (daraxonrasib monotherapy in 2L metastatic PDAC). This is the company's defining near-term catalyst. Global enrollment is officially complete, marking a successful, stable transition from trial accrual to data maturation.
Overcoming Acquired Resistance: The RM-055 Innovation
Management unveiled a new class of RAS(ON) inhibitors designed explicitly to defeat acquired drug resistance. The lead compound, RM-055, drives deep tumor regressions in models that had developed resistance to multi-selective inhibitors. A Phase 1 trial will initiate in Q4 2026. This is a critical technological evolution, proving the company's R&D engine is anticipating the next generation of clinical challenges.
Accelerating G&A Overhead
While R&D increases are expected for Phase 3 trials, G&A expenses are skyrocketing, up 136% YoY in Q4 2025 ($66.7M vs $28.2M). Management attributes this to commercial preparation activities and headcount growth. Scaling a commercial organization years before FDA approval is an aggressive and expensive strategy that significantly amplifies the cash burn.
Execution Complexity of Simultaneous Registrational Trials
Revolution is attempting to run RASolute 302, 303, 304, 305, 309, and RASolve 301 and 308—all simultaneously. Managing crossover risk, clinical supply, site activation, and combination tolerability (especially overlapping toxicities with chemotherapy) across this many pivotal trials is historically perilous for biotech companies of this size.
Insulation from Biotech Funding Macro Environment
While many biotechs face high capital costs and a tight funding macro environment, Revolution Medicines is completely insulated. The $250M drawn from Royalty Pharma in June 2025 leaves $1.75B in committed, non-dilutive capital untouched, backing up an existing $2.0B cash pile. This structural advantage allows them to outspend peers and run multiple parallel trials without constantly tapping equity markets.
Exploding Operating Loss Contradicts 'Runway' Narrative Comfort
The net loss in Q4 2025 reached an astonishing $364.9M. To put this in perspective, total operating expenses in 2024 were $689M; in 2025, they hit $1.18B. Guiding to $1.6B+ for 2026 means expenses are accelerating aggressively. If any major trial requires modification or expansion, the burn rate could force them to tap the Royalty Pharma facility much faster than anticipated.
Other KPIs
Accelerating significantly from -$194.6M in Q4 2024. The quarterly loss nearly doubled YoY, directly reflecting the massive step-up in trial initiation, drug manufacturing for Phase 3 cohorts, and commercial prep activities.
Accelerating. Up 66% from $592.2M in 2024. This line item represents the core engine of the company and shows that management is aggressively funneling capital into the clinical advancement of daraxonrasib, zoldonrasib, and elironrasib.
Stable relative to previous quarters, but down from $2.29B at the end of 2024, despite the $250M influx from the first Royalty Pharma tranche. The sheer volume of the cash balance remains one of the company's primary strategic weapons.
Guidance
Accelerating violently. Compared to total operating expenses of $1.18B in FY25, the midpoint of this guidance ($1.65B) represents an expected ~40% YoY increase. This includes $180M-$200M in non-cash stock compensation, meaning cash burn will easily exceed $1.4B next year.
Key Questions
Tolerability of Zoldonrasib + Daraxonrasib Doublet
You plan to initiate RASolute 309 evaluating the doublet of zoldonrasib plus daraxonrasib in 2H 2026. What specific Phase 1/2 safety and dose-optimization milestones are gating the initiation of this pivotal doublet trial?
G&A Expense Trajectory
G&A expenses accelerated to nearly $67M in Q4. Given the $1.6-$1.7B total OpEx guidance for 2026, what proportion of that is allocated to commercial infrastructure build-out versus pure clinical execution?
Royalty Pharma Capital Drawdowns
With the 2026 cash burn set to exceed $1.4B, what are your expected triggers or timelines for drawing down the remaining $1.75B in the Royalty Pharma facility over the next 12-18 months?